Zolgensma launched in May 2019 in the US for $2.1 million, whilst Zynteglo was launched in the EU in...
Read moreThis study aimed to compare the use of financial agreements for oncology and non-oncology appraisals...
Read moreThis study from 2017 - 2019 compares the outcomes for oncology and non-oncology appraisals conducted...
Read moreIn England, to gain a positive recommendation for use within the NHS from NICE, pharmaceutical produ...
Read moreBy joining together, countries can combine their resources to potentially increase the efficiency of...
Read moreWhat is the future of precision medicine in the EU? The field of precision medicine is a complex are...
Read moreNICE will continue to offer joint advice with the Medicines and Healthcare products Regulatory Agenc...
Read moreConclusion: Blincyto has significant clinical benefits, but that further evidence on cost-effective...
Read moreNHS England continues to develop its pricing and reimbursement expertise by appointing Blake Dark, a...
Read moreNICE's final appraisal indicates that Roche has offered the NHS a discount on the drug, which carrie...
Read more